The expansion will include emerging areas of research in the immune response to tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. Additionally, new T cell
Lenvima is an orally administered molecular targeted agent that selectively inhibits the activities of an array of different molecules including VEGFR, FGFR, RET, KIT and PDGFR. VEGFR, FGFR
BL-8040, which is designed to treat acute myeloid leukemia, as well as other hematological indications, mobilizes cancer cells from the bone marrow and may therefore sensitize these cells
A total of 70 patients have been enrolled in the trial, which is examining the ability of AQX-1125 to reduce pain in female patients with BPS/IC, a chronic
The randomized, double blind and placebo controlled trial, which will be conducted in several European countries, is designed to assess the safety and effects of a two-week treatment
Manufactured using patented nab technology, Abraxane (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) is approved to treat NSCLC patients who are not candidates for potentially curative surgery and/or
Under the deal, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for $5.25bn. Both the companies have created a new consumer healthcare joint venture in which
Belarus is the 21st country to approve the company’s Phase III trial, which is now enrolling patients with advanced primary, not yet treated, head and neck cancer. CEL-SCI
The trial, which evaluated the safety, efficacy and pharmacokinetics of Alprolix, met its primary endpoint and achieved low bleeding rates with once-weekly prophylactic dosing in children. Alprolix is
The acquired business has been reorganized under Mylan N.V., a new public company organized in the Netherlands, which will be led by the former Mylan executive team. As
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.